SCHEMBL1008797

SCHEMBL1008797

O=C(O)C(CC1CCCC1)n1ncc(Oc2cccc(C(F)(F)F)c2)cc1=O

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.39
PPARA Q07869 1/20 0.39
CCR2 P41597 1/20 0.38
FFAR4 Q5NUL3 2/20 0.37
FAAH O00519 1/20 0.37
LTA4H P09960 1/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
ADORA1 P30542 1/20 0.37
GCK P35557 1/20 0.37
EPOR P19235 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007389 0.89 GCK (0.40) FFAR4FAAHLTA4HGCK
SCHEMBL1008862 0.88 NPY5R (0.41)
SCHEMBL1008428 0.87 ABL1 (0.38) PPARGPPARAFFAR4
SCHEMBL1009307 0.87 NPY5R (0.43) FFAR1
SCHEMBL1008255 0.85 CTSS (0.39) ADORA1GCK
SCHEMBL1007920 0.83 KDM4C (0.40) PPARGFAAHLTA4HFFAR1
SCHEMBL1008514 0.82 LPAR1 (0.38) FAAHFFAR1
SCHEMBL1007742 0.82 GPR132 (0.42) FFAR4GCKFFAR1
SCHEMBL1008708 0.82 EPHX1 (0.42) CCR2ALDH1A1GCK
SCHEMBL1008391 0.82 LPAR1 (0.37) FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK PPARG 88/4885PPARA 273/4885CCR2 4153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.